Currently out of the existing stock ratings of Andrew Fein, 29 are a HOLD (3.53%), 793 are a BUY (96.47%).

Andrew Fein

Work Performance Price Targets & Ratings Chart

Analyst Andrew Fein, currently employed at HC WAINWRIGHT, carries an average stock price target met ratio of 47.31% that have a potential upside of 69.76% achieved within 240 days.

Andrew Fein’s has documented 1,539 price targets and ratings displayed on 85 stocks. The coverage is on Healthcare, Industrials, Technology, Energy sectors.

Most recent stock forecast was given on DNLI, Denali Therapeutics at 26-Mar-2026.

Wall Street Analyst Andrew Fein

Analyst best performing recommendations are on CCCC (C4 THERAPEUTICS ).
The best stock recommendation documented was for INSM (INSMED) at 5/14/2024. The price target of $52 was fulfilled within 15 days with a profit of $26.55 (104.32%) receiving and performance score of 69.55.

Average potential price target upside

of $72.29 (47.14%) on CRBP (CORBUS PHARMACEUTICALS).
of $65.48 (23.29%) on UTHR (UNITED THERAPEUTICS).
of $57.69 (28.35%) on BIIB (BIOGEN).

ACAD ACADIA Pharmaceuticals ANNX Annexon BIIB Biogen BLU BELLUS Health BPMC Blueprint Medicines Corp CRTX Cortexyme DBVT DBV Technologies ELOX Eloxx Pharmaceuticals EPZM Epizyme FHTX Foghorn Therapeutics IMAB I-Mab MRUS Merus BV OCUP Ocuphire Pharma PRQR ProQR Therapeutics BV SGEN Seagen AMLX Amylyx Pharmaceuticals DCPH Deciphera Pharmaceuticals LLC GMTX Gemini Therapeutics RUBY Rubius Therapeutics TARA Protara Therapeutics UTHR United Therapeutics AMRN Amarin PLC SYRS Syros Pharmaceuticals ZNTL Zentalis Pharmaceuticals Llc CPRX Catalyst Pharmaceuticals CCCC C4 Therapeutics ARVN Arvinas LQDA Liquidia Technologies ABOS Acumen Pharmaceuticals ACIU AC Immune Ltd CRBP Corbus Pharmaceuticals DNLI Denali Therapeutics FULC Fulcrum Therapeutics KALV Kalvista Pharmaceuticals MEIP MEI Pharma NBIX Neurocrine Biosciences PEPG PepGen Ltd PRTA Prothena plc PULM Pulmatrix STOK Stoke Therapeutics STRO Sutro Biopharma TCRX Tscan Therapeutics THRX Theseus Pharmaceuticals UBX Unity Biotechnology VIGL Vigil Neuroscience VRTX Vertex Pharmaceuticals WVE Wave Life Sciences Ltd ALEC Alector BCRX BioCryst Pharmaceuticals INSM Insmed KMDA Kamada KROS Keros Therapeutics KYMR Kymera Therapeutics SVRA Savara APRE Aprea Therapeutics CNCE Concert Pharmaceuticals GBT Global Blood Therapeutics DYN Dyne Therapeutics RNA Avidity Biosciences BLPH Bellerophon Therapeutics GPCR Structure Therapeutics American Depositary Shares AIMT Aimmune Therapeutics AXON Axon Enterprise CNST Constellation Pharmaceuticals COGT Cogent Biosciences IBRX Immunitybio MTNB Matinas BioPharma Holdings SBBP Strongbridge Biopharma plc SNSS Sunesis Pharmaceuticals ARCT Arcturus Therapeutics Holdings MDGL Madrigal Pharmaceuticals ACST Acasti Pharma AI C3 Ai AKRO Akero Therapeutics BP BP PLC ADR CNC Centene Corp CNS Cohen & Steers ETNB 89bio IMUX Immunic NU Nu Holdings Ltd PTI Proteostasis Therapeutics SG Sweetgreen SY So-Young International TBI TrueBlue BL Blackline

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Tazeen Ahmad (BAML)